On June 4, PegBio (02565.HK) rose 8.52% in regular trading, trading at HKD 8.69/share, with trading volume of HKD 142 million.

On the news front, the company recently released multiple positive developments that converged to extend the stock's rebound momentum. The company's independently developed circular RNA-encoded GLP-1 analogue CR059 research was accepted by the 62nd European Association for the Study of Diabetes annual meeting and selected for an oral discussion session. Additionally, its core commercial product Vepegnatide Injection was included in the 2026 second batch of reference drug pre-communication supplementary disclosure by China's National Healthcare Security Administration, strengthening medical insurance access expectations. The board also proposed a general mandate to repurchase up to 10% of issued H-shares, pending shareholder approval on June 24.

These multiple catalysts, combined with the full release of lock-up selling pressure following the one-year post-IPO share restriction expiry in late May, collectively propelled the stock's continued recovery.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)